01 1Funguard
02 6Funguard/Mycamine
03 1Mycamine
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 257
2019 Revenue in Millions : 322
Growth (%) : -20
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 15
2020 Revenue in Millions : 255
Growth (%) : -94
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2022 Revenue in Millions : 9
2021 Revenue in Millions : 14
Growth (%) : -32
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2022 Revenue in Millions : 107
2021 Revenue in Millions : 116
Growth (%) : -8
Main Therapeutic Indication : Anti-Fungal
Currency : USD
2018 Revenue in Millions : 325
2017 Revenue in Millions : 307
Growth (%) : 6%
Main Therapeutic Indication : Anti-fungal
Currency : USD
2016 Revenue in Millions : 363
2015 Revenue in Millions : 369
Growth (%) : -2
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2019 Revenue in Millions : 326
2018 Revenue in Millions : 336
Growth (%) : -3
Main Therapeutic Indication : Anti-fungal
Currency : USD
2017 Revenue in Millions : 327
2016 Revenue in Millions : 387
Growth (%) : -15
LOOKING FOR A SUPPLIER?
